Working… Menu

Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02161744
Recruitment Status : Terminated (Poor enrollment)
First Posted : June 12, 2014
Last Update Posted : January 27, 2020
Information provided by (Responsible Party):
Arkansas Heart Hospital

Brief Summary:

The purpose of this study is: 1.- to assess the safety and tolerability of autologous adipose derived stem cells (aADSC) administered intravenously in patients with chronic obstructive pulmonary disease, and 2.- to assess if this therapy results in less decrease of lung function parameters (FEV1, FEV1/FVC and 6 min walking distance) compared with a control baseline of 6 weeks.

Patients will be followed up for 12 months after the therapy.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Biological: ADSCs administration Phase 1

Detailed Description:
STUDY DESIGN This is a Phase I open- label single-dose study in subjects with significant COPD. This is an expanded safety cohort. The investigators will enroll a minimum of 30 subjects. 6 week data of FEV1, FEV1/FVC, DLCO and 6 min walking distance values will be collected in all patients who are enrolled in the study (Baseline and 6 weeks after). Prior to the stem cell treatment, the patient will be assessed for 6 weeks by pulmonary function tests and 6 min walk tests. Then, patients will receive the infusion of stromal vascular fraction cells containing the aADSC (single intravenous dose). The standard therapy of COPD patients will not be interrupted during the duration of the study. Safety will be monitored on an ongoing basis, and an interim safety review will be conducted by the Investigator(s) and Sponsor after the first 20 patients have been enrolled and treated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Phase I open label study to assess safety and tolerability
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open- Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Autologous Adipose Stem Cell (Adult Human) to Subjects With Chronic Obstructive Pulmonary Disease
Actual Study Start Date : October 10, 2013
Actual Primary Completion Date : October 29, 2018
Actual Study Completion Date : October 29, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Experimental: ADSCs administration
Patients with Chronic Obstructive Pulmonary Disease will be treated with a single dose of autologous adipose derived stem cells. Stem cells will be isolated using standard Lipoaspiration procedure under sterile conditions.
Biological: ADSCs administration
100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
Other Name: Autologous Adipose Derived Stem Cells

Primary Outcome Measures :
  1. Safety of adipose derived stem cells (ADSC) in Patient with COPD [ Time Frame: 12 months ]
    Safety/tolerability of Adipose Derived Stem Cell (ADSC) in patients with Chronic Obstructive Pulmonary Disease (COPD) during the twelve-month study period as determined by the incidence and severity of of adverse events.

Secondary Outcome Measures :
  1. Efficacy of ADSC in improving Shortness of Breath (SOB) [ Time Frame: 2, 6 and 12 months ]
    The change (decrease) in patient Shortness Of Breath (SOB) as compared to baseline, measured in breath per minute, after administration of adipose derived stem cells (ADSC)

  2. Efficacy of ADSC In Pulmonary Function Test (PFTs) [ Time Frame: 2, 6, 12 months ]
    The change (improvement) in Pulmonary Function Test (PFTs) after administration of adipose derived stem cells (ADSC) as compared to baseline.

  3. Efficacy of adipose derived stem cell in 6 MWT [ Time Frame: 2, 6, 12 months ]
    Improvement in patient ability to walk as measure using a 6 minute walk test ( in meter) as compared to baseline

  4. Efficacy of adipose derived stem cells in patient's perceived exertion. [ Time Frame: 2, 6, 12 months ]
    The change from baseline in patient perceived exertion as measure using the modified BORG scale or Rate of perceive exertion (RPE) which ranges from 1(no perceived exertion at all) to 10 (maximum perceived exertion)

  5. Efficacy in Quality of life using George's Respiratory Questionnaire [ Time Frame: 2, 6, 12 months ]
    The change from baseline in patient quality of life as measure using the George's Respiratory Questionnaire

  6. Efficacy in Quality of life using the Chronic Respiratory questionnaires [ Time Frame: 2, 6, 12 months ]
    The change from baseline in patient quality of life as measure using the Chronic Respiratory Questionnaire

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males and Females ≥18 years.
  2. Cognitive competitiveness.
  3. Diagnosis of at least moderate COPD (postbronchodilator FEV1/FVC < 70% (<0.7), FEV1 < 80% predicted).
  4. Diffusing capacity impairment (DLCO) assessed by single breath test (corrected for alveolar volume, 'DLVA').
  5. Life expectancy greater than 12 months.
  6. Ability to understand and provide signed informed consent, or have a designated legal guardian or spouse legally able and willing to make such decisions on the subject's behalf.
  7. Reasonable expectation that patient will receive standard post-treatment care and attend all scheduled safety follow-up visits.
  8. No changes in active pulmonary medications for heart failure during the two weeks prior enrollment.

10. Written informed consent. 11. Non-smoker or Past smoker, with 20 pack-years or more history

Exclusion Criteria:

  1. Current smokers.
  2. Unstable coronary disease.
  3. Patients with industrial exposure to silica and/or asbestos or giant bullae.
  4. Uncontrolled seizure disorder.
  5. Dementia.
  6. Presence of immune deficiency or autoimmune disease.
  7. Alpha- 1 antitrypsin deficiency.
  8. Cor pulmonale or diastolic heart failure NYHA class III or IV
  9. Type 1 diabetes mellitus
  10. Complicated type 2 diabetes mellitus.
  11. Active tuberculosis or severe lung damage due to tuberculosis (extensive cavitation).
  12. History of cancer within the past 5 years.
  13. Clinically-significant hematologic, hepatic, or renal impairment as determined by screening clinical laboratory tests.
  14. Systemic corticosteroids, cytostatics, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment.
  15. Porphyria.
  16. Allergy to sodium citrate or any "caine" type of local anesthetic.
  17. Abnormal findings could include: known HIV infection or other immunodeficiency state, chronic active viral infection (such as hepatitis B or C), acute systemic infections (defined as patients undergoing treatment with antibiotics), gastrointestinal tract bleeding, or any severe or acute concomitant illness or injury.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02161744

Layout table for location information
United States, Arkansas
Arkansas Heart Hospital
Little Rock, Arkansas, United States, 72211
Arkansas Site Management Services LLC
Little Rock, Arkansas, United States, 72211
Sponsors and Collaborators
Arkansas Heart Hospital
Layout table for investigator information
Principal Investigator: Jason Holder, MD Arkansas Heart Hospital
Layout table for additonal information
Responsible Party: Arkansas Heart Hospital Identifier: NCT02161744    
Other Study ID Numbers: ICMS-2013-25
First Posted: June 12, 2014    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: January 2020
Keywords provided by Arkansas Heart Hospital:
Adipose derived stem cells
Stromal vascular fraction cells
Pulmonary Function Tests
Chronic Obstructive Pulmonary Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases